Maryam Zanjirband

Targeting p53-MDM2 interaction using small molecule inhibitors and the challenges needed to be addressed.

M. Zanjirband, S. Rahgozar, Maryam Zanjirband, 2019, Current drug targets.

miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia

M. Zanjirband, S. Rahgozar, N. Aberuyi, 2023, Cancer drug resistance.

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

N. Curtin, J. Lunec, R. Edmondson, 2017, Oncotarget.

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer

J. Lunec, R. Edmondson, M. Zanjirband, 2016, Oncotarget.

Detection of the ectC Gene in Halomonas Strains by Polymerase Chain Reaction

M. Zanjirband, N. Golbang, R. Kermanshahi, 2008 .

Evaluation of the p53 pathway in polycystic ovarian syndrome pathogenesis and apoptosis enhancement in human granulosa cells through transcriptome data analysis

M. Zanjirband, M. H. Nasr-Esfahani, Z. Safaeinejad, 2023, Scientific reports.

Transcriptomic screening to identify hub genes and drug signatures for PCOS based on RNA-Seq data in granulosa cells

M. Nasr-Esfahani, M. Zanjirband, Maryam Baharlooie, 2023, Comput. Biol. Medicine.

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

Y. Drew, N. Curtin, J. Lunec, 2018, Cancer medicine.